Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates

PR Newswire June 27, 2023

REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit

PR Newswire June 20, 2023

REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference

PR Newswire June 1, 2023

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

PR Newswire May 23, 2023

REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023

PR Newswire May 22, 2023

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio

PR Newswire May 16, 2023

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire May 8, 2023

REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights

PR Newswire May 3, 2023

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting

PR Newswire May 2, 2023

REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights

PR Newswire April 26, 2023

REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PR Newswire April 18, 2023

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

PR Newswire April 11, 2023

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire March 8, 2023

REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

PR Newswire February 28, 2023

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium(TM)

PR Newswire February 24, 2023

Additional Positive Interim Data from Phase I/II/III CAMPSIITE(TM) Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

PR Newswire February 22, 2023

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

PR Newswire February 21, 2023

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium(TM) 2023

PR Newswire February 17, 2023

REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress(TM) Manufacturing Platform Process

PR Newswire February 11, 2023

REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference

PR Newswire February 8, 2023